William Blair Starts Korro Bio Inc. (KRRO) at Outperform

William Blair analyst Myles Minter initiates coverage on Korro Bio Inc. (NASDAQ: KRRO) with a Outperform rating.

The analyst comments "We are initiating coverage of Korro Bio with an Outperform rating and fair value of $180 per share. Korro is a leader in the adenosine deaminase acting on RNA (ADAR) editing field, which aims to perform precise adenosine (A) to inosine (I; interpreted as guanine in translation) substitutions to correct single nucleotide polymorphisms or create de novo proteins of novel function with the goal of diseasemodifying therapies. The company’s proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform combines novel chemistries, computational biology, and delivery systems that recruit endogenous ADAR for RNA editing to selectively correct disease. ADAR editing permits chronic dosing and titratability of a genetic editing medicine without the risk of permanent off-target effects or potential issues with over-/underexpression of target genes. Risks are primarily clinical, regulatory, and commercial in nature, similar to other biotechnology companies."

For an analyst ratings summary and ratings history on Korro Bio Inc. click here. For more ratings news on Korro Bio Inc. click here.

Shares of Korro Bio Inc. closed at $36.36 yesterday.

You May Also Be Interested In

• Trex (TREX) Reiterated at Hold by Benchmark as Partnership Agreement Announced
• FB Financial (FBK) Reiterated at Buy by Benchmark Amid Accelerating Loan Growth
• Stephens Upgrades WESCO International (WCC) to Overweight